论文部分内容阅读
比较河南省新乡人民药厂（A）与国营青岛制药厂（B）生产的法莫替丁片的人体相对生物利用度。方法：8名健康男性受试者口服40mg法莫替丁片后，血药浓度采用高效液相色谱法测定。用中国药理学会制订的实用药物动力学计算程序3P87，计算药动学参数。结果：A厂与B厂的Cmax分别为（122.5±11.9）ng·ml-1和（1179±137）ng·ml－1；Tmax分别为（1.9±0．4）h和（1.9±0．3）h;AUC分别为（709.8±90.6）ng·h·ml－1和（736．1±115.6）ng·h·ml-1，A对B生产的法莫替丁片的相对生物利用度为（97.4±11.3）％。结论：A厂与B厂法莫替丁片等效。
The relative bioavailability of famotidine tablets produced by Henan Xinxiang People’s Pharmaceutical Factory (A) and state-owned Qingdao Pharmaceutical Factory (B) was compared. Methods: Eight healthy male subjects oral administration of 40mg famotidine tablets, plasma concentrations were determined by high performance liquid chromatography. Pharmacokinetic parameters were calculated using a practical pharmacokinetic program, 3P87, developed by the Chinese Pharmacopoeia. Results: The Cmax of plant A and plant B were (122.5 ± 11.9) ng · ml-1 and (1179 ± 137) ng · ml-1, respectively; the Tmax were (1.9 ± 0.4) h and (1.9 ± 0) 3) h; AUC were (709.8 ± 90.6) ng · h · ml-1 and (736.1 ± 115.6) ng · h · ml-1 respectively. The relative bioavailability of A to the famotidine tablets produced by B (97.4 ± 11.3)%. Conclusion: Plant A is equivalent to famotidine in plant B.